Amgen’s Revenue Breakdown by Product (2016-2023)

This statistic highlights Amgen’s Revenue Breakdown by Product, split across Enbrel, Prolia, Neulasta, Otezla, XGEVA, Kyprolis,  Aranesp,and Repatha, reported on a quarterly basis from Q1 2016 onwards.

Amgen’s Revenue by Product

(All figures are in millions)

1. ENBREL

• ENBREL, a tumor necrosis factor blocker, is most commonly used in the United States. ENBREL was approved in 1998 for the treatment of adults with moderately to severely active rheumatoid arthritis, patients with chronic moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
• ENBREL sales fell for Q3 2021 as compared to Q3 2020 due to a decrease in unit demand, unfavorable changes in inventory, and a lower net selling price, which were partially offset by favorable changes in estimated sales deductions.

2. PROLIA

• It is primarily used to treat postmenopausal women with osteoporosis who are at high risk of fracture.
• Higher unit demand drove the increase in global Prolia sales by 14.55% on a year-on-year basis from $701 million in Q3 2020 to $803 million in Q3 2021.

3. NEULASTA

• Neulasta was introduced in 2002 and is primarily used to help reduce the risk of infection caused by a low white blood cell count in patients with certain types of cancer who are receiving anticancer medicines (chemotherapy) that can cause fever and a low blood cell count.
• Decrease in sales was driven by the impact of biosimilar competition on net selling price and unit demand.

4. OTEZLA

• It is an oral therapy that is used for the treatment of adult patients with moderate-to-severe plaque psoriasis who are not candidates for phototherapy or systemic therapy.
• Increase in demand in Q3 2021 as compared to Q1 2020 was powered by higher demand and favorable changes in estimating sales deduction.

5. XGEVA

• XGEVA was launched in 2010 and is used in the prevention of skeletal-related events such as Radiation to Bone, Spinal Cord compression in patients with bone metastases from multiple myeloma and solid tumor.
• The sales increase was primarily because of an increment in demand, partially offset by a decrease in net selling price.

6. KYPROLIS

• It is used to treat patients with relapsed or refractory multiple myeloma that have received one to three prior lines of therapy with dexamethasone or lenalidomide plus dexamethasone.
• There was a year-on-year growth by 12.7% , driven by higher units demand in Q3 2021 compared to Q3 2020.

7. ARANESP

• It was approved in 2001 to treat anaemia (lower-than-normal number of red blood cells) caused by chronic kidney disease (CKD) in both dialysis and non-dialysis patients.
• A quarter-on-quarter growth in revenue by 7.90%  from $367 million in Q2 2021 to $396 million in Q3 2021 was directed by higher demand and favorable changes in estimating sales deduction.

8. REPATHA

• Repatha was approved in 2015 to reduce the risks of myocardial infarction, stroke, and coronary revascularization in adults with established cardiovascular disease.
• Growth in sales by 32.7% was due to an increase in demand which is partially offset by lower net selling price in Q3 2021 as compared to Q3 2020.

About the company

Amgen Inc. (formerly Applied Molecular Genetics Inc.) is a biopharmaceutical multinational headquartered in Thousand Oaks, California. It is the world’s largest independent biotechnology company, founded in 1980. The firm specializes in biochemistry and molecular biology. Amgen is dedicated to maximizing the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing, and distributing novel human therapeutics. This approach begins with the application of tools such as advanced human genetics to decipher disease complexities and comprehend the fundamentals of human biology.

Did you like Amgen’s Revenue Breakdown by Product statistic?

Access more such key performance indicator data points, on thousands of US stocks, with Business Quant.

You can also get started for free.